39 related articles for article (PubMed ID: 33449608)
1. Incidence and risk factors of graft-versus-host disease after liver transplantation: A national study 2010-2020.
Huang Y; Wang Y; Chase RC; Yang L
Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37756119
[TBL] [Abstract][Full Text] [Related]
2. Graft-versus-host disease following liver transplantation: A systematic review of literature.
Kneifel F; Vogel T; Bormann E; Becker F; Houben P; Flammang I; Slepecka P; Eichelmann AK; Brockmann JG; Pascher A
Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37755878
[TBL] [Abstract][Full Text] [Related]
3. Graft-versus-Host Disease-Like Pattern in Mycophenolate Mofetil Related Colon Mucosal Injury: Role of FISH in Establishing the Diagnosis.
Behling KC; Foster DM; Edmonston TB; Witkiewicz AK
Case Rep Gastroenterol; 2009 Dec; 3(3):418-423. PubMed ID: 21103265
[TBL] [Abstract][Full Text] [Related]
4. Acute graft versus host disease after liver transplantation: where do we stand?
Izzo A; Pellegrino RA; Locci G; Cesaretti M
Minerva Surg; 2023 Oct; 78(5):537-544. PubMed ID: 36883938
[TBL] [Abstract][Full Text] [Related]
5. Outcomes in Living Donor Compared With Deceased Donor Primary Liver Transplantation in Lower Acuity Patients With Model for End-Stage Liver Disease Scores <30.
Kitajima T; Moonka D; Yeddula S; Collins K; Rizzari M; Yoshida A; Abouljoud MS; Nagai S
Liver Transpl; 2021 Jul; 27(7):971-983. PubMed ID: 33492764
[TBL] [Abstract][Full Text] [Related]
6. Reply.
Kitajima T; Moonka D; Yeddula S; Collins K; Rizzari M; Yoshida A; Abouljoud MS; Nagai S
Liver Transpl; 2021 Aug; 27(8):1217-1218. PubMed ID: 33786986
[No Abstract] [Full Text] [Related]
7. Graft-versus-host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutations.
Newell LF; Dunlap J; Gatter K; Bagby GC; Press RD; Cook RJ; Fletcher L; Leonard JT; Leong KM; Bubalo JS; Olyaei A; Deloughery TG; Maziarz RT; Maynard E; Orloff SL; Enestvedt CK
Am J Transplant; 2021 Dec; 21(12):3894-3906. PubMed ID: 33961341
[TBL] [Abstract][Full Text] [Related]
8. One-way donor-to-recipient human leukocyte antigen mismatch and graft-versus-host disease in liver transplantation: an observational study of a single-center experience in Korea.
Yim SH; Kim DG; Lee JG; Joo DJ; Kim MS
Korean J Transplant; 2023 Dec; 37(4):269-276. PubMed ID: 37994082
[TBL] [Abstract][Full Text] [Related]
9. Dermatologic manifestations of acute graft versus host disease after liver transplantation: A case series of 8 patients.
Kaur M; Singh N; Mital R; Schenk A; Fisher K; Korman AM; Kaffenberger BH; Chung CG
JAAD Case Rep; 2023 Sep; 39():6-13. PubMed ID: 37554362
[No Abstract] [Full Text] [Related]
10. Single-cell RNA-seq revealing the immune features of donor liver during liver transplantation.
Shan Y; Qi D; Zhang L; Wu L; Li W; Liu H; Li T; Fu Z; Bao H; Song S
Front Immunol; 2023; 14():1096733. PubMed ID: 36845096
[TBL] [Abstract][Full Text] [Related]
11. The clinical impact of donor against recipient HLA one way mismatch on the occurrence of graft versus host disease in liver transplantation.
Kim SJ; Park S; Rhu J; Kim JM; Choi GS; Joh JW
Sci Rep; 2022 Nov; 12(1):20337. PubMed ID: 36434131
[TBL] [Abstract][Full Text] [Related]
12. Weight-based mycophenolate mofetil dosing predicts acute GVHD and relapse after allogeneic hematopoietic cell transplantation.
Bejanyan N; Rogosheske J; Cao Q; Lazaryan A; Holtan S; Ustun C; Jacobson P; MacMillan M; Weisdorf DJ; Wagner J; Arora M; Brunstein CG
Eur J Haematol; 2021 Feb; 106(2):205-212. PubMed ID: 33084139
[TBL] [Abstract][Full Text] [Related]
13. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn JY; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491
[TBL] [Abstract][Full Text] [Related]
14. Graft-versus-host disease after liver transplantation: a comprehensive literature review.
Akbulut S; Yilmaz M; Yilmaz S
World J Gastroenterol; 2012 Oct; 18(37):5240-8. PubMed ID: 23066319
[TBL] [Abstract][Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
16. Incidence and Risk Factors for Fatal Graft-versus-host Disease After Liver Transplantation.
Kitajima T; Henry M; Ivanics T; Yeddula S; Collins K; Rizzari M; Yoshida A; Abouljoud MS; Nagai S; Moonka D
Transplantation; 2021 Dec; 105(12):2571-2578. PubMed ID: 33449608
[TBL] [Abstract][Full Text] [Related]
17. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
